Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis

References

• North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006;13:340–367
   PubMed Web of Science ®Google Scholar
• Curtis JR, McClure LA, Delzell E, et al Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med 2009;24:956–962
   PubMed Web of Science ®Google Scholar
• Caliri A, De Filippis L, Bagnato GL, Bagnato GF. Osteoporotic fractures: mortality and quality of life. Panminerva Med 2007;49:21–27
   PubMed Web of Science ®Google Scholar
• Desai SS, Duncan BS, Sloan AS. The cost of treating osteoporosis in a managed health care organization. J Manag Care Pharm 2003;9:142–149
   PubMedGoogle Scholar
• Gold DT. The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes. Rheum Dis Clin North Am 2001;27:255–262
   PubMed Web of Science ®Google Scholar
• Salaffi F, Cimmino MA, Malavolta N, et al The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 2007;34:1551–1560
   PubMed Web of Science ®Google Scholar
• MacLean C, Newberry S, Maglione M, et al Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197–213
   PubMed Web of Science ®Google Scholar
• Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 2001;949:317–326
   PubMed Web of Science ®Google Scholar
• Arun B, Anthony M, Dunn B. The search for the ideal SERM. Expert Opin Pharmacother 2002;3:681–691
   PubMedGoogle Scholar
• Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 2007;24:361–379
   PubMed Web of Science ®Google Scholar
• Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999–4008
   PubMed Web of Science ®Google Scholar
• Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009;150:1897–1903
   PubMed Web of Science ®Google Scholar
• Ronkin S, Clarke L. TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion. J Bone Miner Res 2001;16(Suppl 1):S413 [abstract SU437]
   Google Scholar
• Ronkin S, Northington R, Baracat E, et al Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397–1404
   PubMed Web of Science ®Google Scholar
• Miller PD, Chines AA, Christiansen C, et al Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525–535
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, et al Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 2008;23:1923–1934
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009;44:1049–1054
   PubMed Web of Science ®Google Scholar
• Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of Osteoporosis at the Primary Health Care Level. Technical report. Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases, 2008
   Google Scholar
• Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385–397
   PubMed Web of Science ®Google Scholar
• World Health Organization. Assessment of osteoporosis at the primary health care level. Summary Report of a WHO Scientific Group. Geneva: World Health Organization, 2007. http://www.who.int/chp/topics/rheumatic/en/index.html [serial online]; Accessed March 5, 2009
   Google Scholar
• McCloskey E, Johansson H, Oden A, Chines A, Kanis J. Assessment of the effect of bazedoxifene on non-vertebral fracture risk. J Bone Miner Res 2009;24(Suppl 1). Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6c55b263-692e-4a37-b807-f7a153641564. Accessed October 26, 2009
   PubMedGoogle Scholar
• Silverman S, Chines A, Zanchetta JR, et al Sustained efficacy of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. J Bone Miner Res 2009;24(Suppl 1). Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=2643ea2f-c4ab-4eb6-9798-09050bb21b6b. Accessed October 15, 2009
   PubMedGoogle Scholar
• de Villiers TJ, Kendler D, Chines A, et al Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. J Bone Miner Res 2009;24(Suppl 1). Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=1dae18c8-99a0-4757-957b-689b21823623. Accessed October 15, 2009
   Google Scholar
• Fleischer AC, Wheeler JE, Yeh IT, Kravitz B, Jensen C, MacDonald B. Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J Ultrasound Med 1999;18:503–512
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 2002;187:521–527
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Archer DF, Utian WH, et al Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 2009;16:1102–1108
   PubMed Web of Science ®Google Scholar
• Archer DF, Pinkerton JV, Utian WH, et al Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009;16:1109–1115
   PubMed Web of Science ®Google Scholar
• Harvey JA, Holm MK, Ranganath R, Guse PA, Trott EA, Helzner E. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 2009;16:1193–1196
   PubMed Web of Science ®Google Scholar
• Palacios S, Menegoci JC, Kelepouris N, Constantine GD, de Villiers TJ. Endometrial and breast safety of bazedoxifene in postmenopausal women with osteoporosis: findings from a 5-year, randomized, placebo-controlled phase 3 trial. Menopause 2009;16:1263
   Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637–645
   PubMed Web of Science ®Google Scholar
• Grady D, Ettinger B, Moscarelli E, et al Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 2004;104:837–844
   PubMed Web of Science ®Google Scholar
• Adachi JD, Chesnut CH, Brown JP, et al Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. Poster presented at 35th European Symposium on Calcified Tissues, May 24–28, 2008, Barcelona, Spain
   Google Scholar
• Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084–6091
   PubMed Web of Science ®Google Scholar
• Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci 2008;15:984–992
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML, et al Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025–1038
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045–1052
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018–1024
   PubMed Web of Science ®Google Scholar
• Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039–1044
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116–1124
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women [published online ahead of print September 25, 2009]. Menopause doi:10.1097/GME.0b013e3181b7c65f
   Google Scholar
• National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. http://www.nof.org/professionals/Clinicians_Guide.htm [serial online]; Accessed October 28, 2009
   Google Scholar
• Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update. J Oral Maxillofac Surg 2009;67:2–12
   PubMed Web of Science ®Google Scholar
• Solomon DH, Rekedal L, Cadarette SM. Osteoporosis treatments and adverse events. Curr Opin Rheumatol 2009;21:363–368
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services, Public Health Service, Food and Drug Administration. ODS Postmarketing Safety Review. FDA osteonecrosis statement. 2004
   Google Scholar
• International Osteoporosis Foundation. Osteonecrosis of the jaw. http://www.iofbonehealth.org/health-professionals/special-topics/osteonecrosis-of-jaw.html [serial online]; Accessed August 10, 2009
   Google Scholar
• Cummings SR, Eckert S, Krueger KA, et al The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189–2197
   PubMed Web of Science ®Google Scholar
• Martino S, Cauley JA, Barrett-Connor E, et al Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751–1761
   PubMed Web of Science ®Google Scholar
• Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929–1936
   PubMed Web of Science ®Google Scholar